Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7608976 | 1.00 | LOXL2 (0.54) | LOXL2CYP4A11CYP4F2RAB9ANPC1 | |
| SCHEMBL9133875 | 0.85 | CYP4A11 (0.57) | LOXL2CYP4A11CYP4F2RAB9ANPC1 | |
| SCHEMBL2131336 | 0.84 | CA12 (0.53) | RAB9ANPC1SMN1; SMN2MAPTCA1 | |
| SCHEMBL9181993 | 0.82 | PRSS1 (0.44) | SMN1; SMN2MAPTMEN1KMT2ALMNA | |
| SCHEMBL9232501 | 0.81 | LOXL2 (0.49) | LOXL2CYP4A11CYP4F2RAB9ANPC1 | |
| SCHEMBL13560681 | 0.81 | KMT2A (0.53) | RAB9ASMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL28587445 | 0.80 | LOXL2 (0.44) | LOXL2CYP4A11CYP4F2RAB9ANPC1 | |
| SCHEMBL31352725 | 0.79 | LOXL2 (0.58) | LOXL2CYP4A11CYP4F2MAPTCA1 | |
| SCHEMBL2783327 | 0.79 | ALDH1A1 (0.48) | SMN1; SMN2MAPTTDP1MEN1KMT2A | |
| SCHEMBL14063048 | 0.78 | TP53 (0.42) | SMN1; SMN2MAPTKMT2ATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9057018-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, and polymer thereof | JNC CORPORATION (JP) | 2015-06-16 | — | — | US | disclosed |
| US-8425988-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition and anisotropic polymer | JNC CORPORATION (JP) | 2013-04-23 | — | — | US | disclosed |
| US-20110147657-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND ANISOTROPIC POLYMER | CHISSO CORPORATION (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20100304148-A1 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, and polymer thereof | CHISSO CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100297367-A1 | OPTICALLY ANISOTROPIC SUBSTANCE | CHISSO CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| US-6395919-B1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION | 2002-05-28 | — | — | US | disclosed |
| EP-1070048-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-1070048-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999051569-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100304148-A1 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, and polymer thereof | SSB, CNKSR1, RCC1 | LOXL2 1150/4885CYP4A11 1808/4885CYP4F2 3128/4885 |
| US-20110147657-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND ANISOTROPIC POLYMER | SSB, LEF1, UACA | LOXL2 2432/4885CYP4A11 1232/4885CYP4F2 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.